Citations

Clear

4801 citation(s) found for "Yu, Jennifer".

A Genome-Wide Gene-Based Gene–Environment Interaction Study of Breast Cancer in More than 90,000 Women
Chen, Hongjie , Middha, Pooja , Bolla, Manjeet K. , Wang, Qin , Michailidou, Kyriaki , Hopper, John L. , Shibli, Rana , Aronson, Kristan J. , Hodge, James M. , Brenner, Hermann , Hoppe, Reiner , Lo, Wing‐Yee, Mannermaa, Arto , Kosma, Veli‐Matti , Jung, Audrey , Haiman, Christopher A. , Simard, Jacques , Goldberg, Mark S. , García‐Closas, Montserrat , Yang, Rose, Evans, D. Gareth , Howell, Anthony , Orr, Nick , Wang, Sophia , Easton, Douglas F. , Chang‐Claude, Jenny , Lindström, Sara , Winham, Stacey, Evans, D Gareth , Brenner, Hermann , Kapoor, Pooja Middha , García-Closas, Montserrat , Michailidou, Kyriaki , Hodge, James M , Simard, Jacques , Wang, Sophia S , Jung, Audrey Y , Orr, Nick , Wang, Xiaoliang , Su, Yu-Ru , Dennis, Joe , Dunning, Alison M. , Lush, Michael J. , Pharoah, Paul D.P. , Southey, Melissa C. , Koutros, Stella , Freeman, Laura E. Beane , Stone, Jennifer , Rennert, Gad , Murphy, Rachel A. , Guénel, Pascal , Truong, Thérèse , Teras, Lauren R. , Canzian, Federico , Kaaks, Rudolf , Arndt, Volker , Behrens, Sabine , Becher, Heiko , Giles, Graham G. , Maskarinec, Gertraud , Scott, Christopher G. , Winham, Stacey J. , Zheng, Wei , Long, Jirong , Troester, Melissa A. , Love, Michael I. , Peng, Cheng , Tamimi, Rulla M. , Eliassen, A. Heather , Figueroa, Jonine D. , Ahearn, Thomas U. , Hall, Per N , Czene, Kamila , Wolk, Alicja , Sandler, Dale P. , Taylor, Jack A. , Swerdlow, Anthony J. , Lacey, James V. , Olsson, Håkan , Milne, Roger L. , Hsu, Li , Kraft, Peter

Mayo Clinic

Cancer Research Communications | March 25, 2022 | Volume: 2 | Issue: 4 | Pages: 211-219

10.1158/2767-9764.crc-21-0119 | PMID 36303815 Get It

Genome-wide association studies (GWAS) have identified more than 200 susceptibility loci for breast cancer, but these variants explain less than a fifth of the disease risk. Although gene–environment interactions have been proposed to account for some of the remaining heritability, few studies have empirically assessed this. We obtained genotype and risk factor data from 46,060 cases and 47,929 controls of European ancestry from population-based studies within the Breast Cancer Association Consortium (BCAC). We built gene expression prediction models for 4,864 genes with a significant (P < 0.01) heritable component using the transcriptome and genotype data from the Genotype-Tissue Expression (GTEx) project. We leveraged predicted gene expression information to investigate the interactions between gene-centric genetic variation and 14 established risk factors in association with breast cancer risk, using a mixed-effects score test. After adjusting for number of tests using Bonferroni correction, no interaction remained statistically significant. The strongest interaction observed was between the predicted expression of the C13orf45 gene and age at first full-term pregnancy (PGXE = 4.44 × 10−6). In this transcriptome-informed genome-wide gene–environment interaction study of breast cancer, we found no strong support for the role of gene expression in modifying the associations between established risk factors and breast cancer risk. Our study suggests a limited role of gene–environment interactions in breast cancer risk.
Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance)
Kulke, Matthew H. , Ou, Fang-Shu, Niedzwiecki, Donna, Huebner, Lucas, Kunz, Pamela L. , Kennecke, Hagen F, Wolin, Edward M, Chan, Jennifer A, O’Reilly, Eileen M, Meyerhardt, Jeffrey A, Venook, Alan, Niedzwiecki, Donna , Meyerhardt, Jeffrey A. , Kunz, Pamela , Meyerhardt, Jeffrey A , Niedzwiecki, Donna , Kulke, Matthew H , Ou, Fang-Shu, Huebner, Lucas, Kennecke, Hagen F, Wolin, Edward M, Chan, Jennifer A, O’Reilly, Eileen M, Venook, Alan

Mayo Clinic

Endocrine-Related Cancer | March 25, 2022 | Volume: 29 | Issue: 6 | Pages: 335-344

10.1530/erc-21-0239 | PMID 35324465 Get It

Treatment with the MTOR inhibitor everolimus improves progression-free survival (PFS) in pancreatic neuroendocrine tumors (pNETs), but it is not known if the addition of a VEGF pathway inhibitor to an MTOR inhibitor enhances antitumor activity. We performed a randomized phase II study evaluating everolimus with or without bevacizumab in patients with advanced pNETs. One hundred and fifty patients were randomized to receive everolimus 10 mg daily with or without bevacizumab 10 mg/kg i.v. every 2 weeks. Patients also received standard dose of octreotide in both arms. The primary endpoint was PFS, based on local investigator review. Treatment with the combination of everolimus and bevacizumab resulted in improved progression-free survival compared to everolimus (16.7 months compared to 14.0 months; one-sided stratified log-rank P = 0.1028; hazard ratio (HR) 0.80 (95% CI 0.56–1.13)), meeting the predefined primary endpoint. Confirmed tumor responses were observed in 31% (95% CI 20%, 41%) of patients receiving combination therapy, as compared to only 12% (95% CI 5%, 19%) of patients receiving treatment with everolimus ( P = 0.0053). Median overall survival duration was similar in the everolimus and combination arm (42.5 and 42.1 months, respectively). Treatment-related toxicities were more common in the combination arm. In summary, treatment with everolimus and bevacizumab led to superior PFS and higher response rates compared to everolimus in patients with advanced pNETs. Although the higher rate of treatment-related adverse events may limit the use of this combination, our results support the continued evaluation of VEGF pathway inhibitors in pNETs.
Stent Evaluation for Expiratory Central Airway Collapse
Majid, Adnan , Ospina-Delgado, Daniel , Gangadharan, Sidhu P. , Alape, Daniel , Buitrago, Daniel, Parikh, Mihir , Wilson, Jennifer L. , Chee, Alex C, Fernández-Bussy, Sebastián , Herth, Felix , Kheir, Fayez , Ayala, Alvaro, Chee, Alex C

Mayo Clinic

Journal of Bronchology & Interventional Pulmonology | March 23, 2022 | Volume: 30 | Issue: 1 | Pages: 37-46

10.1097/lbr.0000000000000842 | PMID 35318996 Get It

Background: Careful selection of patients with expiratory central airway collapse (ECAC) that may benefit from tracheobronchoplasty (TBP) can be aided by a short-term airway stent evaluation. This can be performed with either silicone Y-stents (SYSs) or uncovered self-expanding metallic airway-stents (USEMAS). No direct comparison has been made between these 2 stent types. Methods: This was a small retrospective review of consecutive patients that underwent a stent evaluation. A propensity score was used to match patients in the USEMAS and SYS groups. Outcomes included complications, changes in the health-related quality-of-life (HR-QoL), and changes in exercise capacity. Baseline measurements were compared with those obtained during stent evaluation and after TBP. Results: Forty-two patients with severe ECAC underwent USEMAS placement, while 18 patients had an SYS placed. Propensity score matching resulted in 13 matched SYS and USEMAS pairs. The SYS group had an increased rate of mucus plugging (38.5% vs. 0%, P<0.047). Although not statically significant, a clinical improvement was observed in HR-QoL and exercise capacity in the USEMAS group during stent placement. In patients who underwent TBP, both USEMAS and SYS groups had a statistically significant change in the Modified Medical Research Council Dyspnea Scale during stent evaluation and after TBP. Conclusion: In patients with severe ECAC, short-term evaluation with airway stents appears to be safe and improves respiratory symptoms, HR-QoL, and exercise capacity. The use of USEMAS led to a lower complication rate, a greater improvement in HR-QoL and exercise capacity, and appeared to better predict how the patients would respond to TBP.
Late Complications of COVID-19
Roden, Anja C. , Johnson, Tucker F. , Aubry, Marie Christine, Butt, Yasmeen M. , Maleszewski, Joseph J. , Larsen, Brandon T. , Tazelaar, Henry D. , Khoór, András , Moua, Teng , Jenkins, Sarah M. , Moyer, Ann M. , Yi, Eunhee , Bois, Melanie C. , Boland, Jennifer M. , Lo, Ying‐Chun , Tazelaar, Henry D. , Smith, Maxwell L. , Yi, Eunhee S.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | March 23, 2022 | Volume: 146 | Issue: 7 | Pages: 791-804

10.5858/arpa.2021-0519-sa | PMID 35319744 Get It

Context.— Studies of lungs in patients with COVID-19 have focused on early findings. Objective.— To systematically study histopathologic and imaging features and presence of SARS-CoV-2 RNA in lung tissue from patients in later stages of COVID-19. Design.— Autopsies, explants, surgical lung biopsies, transbronchial biopsies, cryobiopsies, and needle biopsies from patients with COVID-19 whose onset of symptoms/confirmed diagnosis was more than 28 days before the procedure were studied. Available images were reviewed. Reverse transcription droplet digital polymerase chain reaction for SARS-CoV-2 RNA was performed on lung tissue. Results.— Of 44 specimens (43 patients; median age, 59.3 years; 26 [60.5%] male) features of acute lung injury (ALI) were seen in 39 (88.6%), predominantly organizing pneumonia and diffuse alveolar damage, up to 298 days after onset of COVID-19. Fibrotic changes were found in 33 specimens (75%), most commonly fibrotic diffuse alveolar damage (n = 22) and cicatricial organizing pneumonia (n = 12). Time between acquiring COVID-19 and specimen was shorter in patients with diffuse ALI (median, 61.5 days) compared with patients with focal (140 days) or no ALI (130 days) (P = .009). Sixteen (of 20; 80%) SARS-CoV-2 reverse transcription droplet digital polymerase chain reaction tests were positive, up to 174 days after COVID-19 onset. Time between COVID-19 onset and most recent computed tomography in patients with consolidation on imaging was shorter (median, 43.0 days) versus in patients without consolidation (87.5 days; P = .02). Reticulations were associated with longer time to computed tomography after COVID-19 onset (median, 82 versus 23.5 days; P = .006). Conclusions.— ALI and SARS-CoV-2 RNA can be detected in patients with COVID-19 for many months. ALI may evolve into fibrotic interstitial lung disease.
Dysregulation of serum prolactin links the hypothalamus with female nociceptors to promote migraine
Watanabe, Moe, Kopruszinski, Caroline Machado , Moutal, Aubin , Ikegami, Daigo , Chen, Yanxia , Ross, Sarah, Mackenzie, Kimberly D., Stratton, Jennifer , Navratilova, Edita , Kopruszinski, Caroline , Khanna, Rajesh , Dodick, David W. , Navratilova, Edita , Porreca, Frank

Mayo Clinic

Brain | March 22, 2022 | Volume: 145 | Issue: 8 | Pages: 2894-2909

10.1093/brain/awac104 | PMID 35325034 Get It

AbstractMigraine headache results from activation of meningeal nociceptors, however, the hypothalamus is activated many hours before the emergence of pain. How hypothalamic neural mechanisms may influence trigeminal nociceptor function remains unknown. Stress is a common migraine trigger that engages hypothalamic dynorphin/kappa opioid receptor (KOR) signalling and increases circulating prolactin. Prolactin acts at both long and short prolactin receptor isoforms that are expressed in trigeminal afferents. Following downregulation of the prolactin receptor long isoform, prolactin signalling at the prolactin receptor short isoform sensitizes nociceptors selectively in females. We hypothesized that stress may activate the kappa opioid receptor on tuberoinfundibular dopaminergic neurons to increase circulating prolactin leading to female-selective sensitization of trigeminal nociceptors through dysregulation of prolactin receptor isoforms.A mouse two-hit hyperalgesic priming model of migraine was used. Repeated restraint stress promoted vulnerability (i.e. first-hit priming) to a subsequent subthreshold (i.e. second-hit) stimulus from inhalational umbellulone, a TRPA1 agonist. Periorbital cutaneous allodynia served as a surrogate of migraine-like pain. Female and male KORCre; R26lsl-Sun1-GFP mice showed a high percentage of KORCre labelled neurons co-localized in tyrosine hydroxylase-positive cells in the hypothalamic arcuate nucleus. Restraint stress increased circulating prolactin to a greater degree in females. Stress-primed, but not control, mice of both sexes developed periorbital allodynia following inhalational umbellulone. Gi-DREADD activation (i.e. inhibition through Gi-coupled signalling) in KORCre neurons in the arcuate nucleus also increased circulating prolactin and repeated chemogenetic manipulation of these neurons primed mice of both sexes to umbellulone. Clustered regularly interspaced short palindromic repeats–Cas9 deletion of the arcuate nucleus KOR prevented restraint stress-induced prolactin release in female mice and priming from repeated stress episodes in both sexes. Inhibition of circulating prolactin occurred with systemic cabergoline, a dopamine D2 receptor agonist, blocked priming selectively in females. Repeated restraint stress downregulated the prolactin receptor long isoform in the trigeminal ganglia of female mice. Deletion of prolactin receptor in trigeminal ganglia by nasal clustered regularly interspaced short palindromic repeats–Cas9 targeting both prolactin receptor isoforms prevented stress-induced priming in female mice.Stress-induced activation of hypothalamic KOR increases circulating prolactin resulting in trigeminal downregulation of prolactin receptor long and pain responses to a normally innocuous TRPA1 stimulus. These are the first data that provide a mechanistic link between stress-induced hypothalamic activation and the trigeminal nociceptor effectors that produce trigeminal sensitization and migraine-like pain. This sexually dimorphic mechanism may help to explain female prevalence of migraine. KOR antagonists, currently in phase II clinical trials, may be useful as migraine preventives in both sexes, while dopamine agonists and prolactin/ prolactin receptor antibodies may improve therapy for migraine, and other stress-related neurological disorders, in females.
Accelerated hypofractionated radiation for elderly or frail patients with a newly diagnosed glioblastoma: A pooled analysis of patient‐level data from 4 prospective trials
Perlow, Haley K. , Prasad, Rahul N. , Yang, Mike, Klamer, Brett , Matsui, Jennifer K. , Scorsetti, Marta , Clerici, Elena , Arnett, Andrea , Beyer, Sasha , Ammirati, Mario , Chakravarti, Arnab , Raval, Raju R. , Brown, Paul D. , Navarria, Pierina , Scoccianti, Silvia , Grecula, J.C., Chakravarti, Arnab , Brown, Paul D , Palmer, Joshua D , Perlow, Haley K , Chakravarti, Arnab , Scorsetti, Marta , Marrazzo, L. , Detti, Beatrice , Palmer, Joshua D.

Mayo Clinic

Cancer | March 22, 2022 | Volume: 128 | Issue: 12 | Pages: 2367-2374

10.1002/cncr.34192 | PMID 35315512 Get It

BackgroundThe standard of care for elderly or frail patients with glioblastoma (GBM) is 40 Gy in 15 fractions of radiotherapy. However, this regimen has a lower biological effective dose (BED) compared with the Stupp regimen of 60 Gy in 30 fractions. It is hypothesized that accelerated hypofractionated radiation of 52.5 Gy in 15 fractions (BED equivalent to Stupp) is safe and efficacious.MethodsElderly or frail patients with GBM treated with 52.5 Gy in 15 fractions were pooled from 3 phase 1/2 studies and a prospective observational study. Overall survival (OS) and progression‐free survival (PFS) were defined time elapsing between surgery/biopsy and death from any cause or progression of disease.ResultsSixty‐two newly diagnosed patients were eligible for this pooled analysis of individual patient data. The majority (66%) had a Karnofsky performance status (KPS) score <70. The median age was 73 years. The median OS and PFS were 10.3 and 6.9 months, respectively. Patients with KPS scores ≥70 and <70 had a median OS of 15.3 and 9.5 months, respectively. Concurrent chemotherapy was an independent prognostic factor for improved PFS and OS. Grade 3 neurologic toxicity was seen in 2 patients (3.2%). There was no grade 4/5 toxicity.ConclusionsThis is the only analysis of elderly/frail patients with GBM prospectively treated with a hypofractionated radiation regimen that is isoeffective to the Stupp regimen. Treatment was well tolerated and demonstrated excellent OS and PFS compared with historical studies. This regimen gives the elderly/frail population an alternative to regimens with a lower BED. Randomized trials are needed to validate these results.
Quality of life metrics in LVAD patients after hemocompatibility‐related adverse events
Weber, Matthew P. , Stulak, John M., Maltais, Simon, Tchantchaleishvili, Vakhtang , Weber, Matthew P , Pagani, Francis D. , Cowger, Jennifer , Tchantchaleishvili, Vakhtang

Mayo Clinic

Artificial Organs | March 22, 2022 | Volume: 46 | Issue: 8 | Pages: 1616-1625

10.1111/aor.14235 | PMID 35315092 Get It

Abstract Background Hemocompatibility‐related adverse events (HRAE) negatively influence survival. However, no study has examined the impact of these events on health‐related quality of life (HRQOL) and functional outcomes following continuous‐flow left ventricular assist device implantation (CF‐LVAD). We assessed the impact of HRAE events on HRQOL and hypothesized that HRAE's adversely impact HRQOL and functional outcomes. Methods INTERMACS database identified patients undergoing primary CF‐LVAD implantation from 2008 to 2017. HRAEs included stroke, non‐surgical bleeding, hemolysis, and pump thrombosis and were identified as defined in the literature. HRAEs were further stratified as Tier 1–2 and disabling stroke events. Time‐series analysis was executed for HRAE patients with values pre‐HRAE, post‐HRAE, and closest to 12 months follow up. Local polynomial regression curves modeling individual patients were superimposed into “spaghetti” plots. Results All HRQOL and functional metrics improved in patients over time, despite HRAE complications. However, these patient metrics were significantly reduced compared to the non‐HRAE cohort. Advanced data visualization techniques noted a decline after experiencing an HRAE with a subsequent recovery to baseline levels or higher. Six‐minute walk test (6MWT) was noted to be most affected in the post‐HRAE period but recovered similar to other metrics. Conclusions The burden of HRAE following CF‐LVAD implantation did not negatively impact the quality of life. However, the 6MWT did not increase in the post‐HRAE period in all HRAE patients. Improvement of heart failure symptoms after CF‐LVAD coupled with optimal management following the HRAE act to preserve the enhanced quality of life.
Characterizing Amyloid-Positive Individuals With Normal Tau PET Levels After 5 Years
Josephs, Keith A. , Weigand, Stephen D. , Whitwell, Jennifer L. , Whitwell, Jennifer L.

Mayo Clinic

Neurology | March 21, 2022 | Volume: 98 | Issue: 22 | Pages: No page available

10.1212/wnl.0000000000200287 | PMID 35314506 Get It

Social Media and Professional Development for Oncology Professionals
Chidharla, Anusha , Attai, Deanna J. , Drake, Emily K. , Londen, G. J. van , Subbiah, Ishwaria M. , Henry, Elizabeth , Murphy, Martina, Barry, Maura , Manochakian, Rami , Leyfman, Yan , Utengen, Audun , Attai, Deanna J , Drake, Emily K , van Londen, G J , Subbiah, Ishwaria M , Henry, Elizabeth , Barry, Maura M , Manochakian, Rami , Moerdler, Scott , Loeb, Stacy , Graff, Stephanie L , Leyfman, Yan , Thompson, Michael A , Markham, Merry J , Utengen, Audun , Loeb, Stacy , Graff, Stephanie L. , Thompson, Michael A, Markham, Merry Jennifer

Mayo Clinic

JCO Oncology Practice | March 21, 2022 | Volume: 18 | Issue: 8 | Pages: 566-571

10.1200/op.21.00761 | PMID 35312343 Get It

The use of social media continues to increase in health care and academia. Health care practice, particularly the oncologic field, is constantly changing because of new knowledge, evidence-based research, clinical trials, and government policies. Therefore, oncology trainees and professionals continue to strive to stay up-to-date with practice guidelines, research, and skills. Although social media as an educational and professional development tool is no longer completely new to medicine and has been embraced, it is still under-researched in terms of various outcomes. Social media plays several key roles in professional development and academic advancement. We reviewed the literature to evaluate how social media can be used for professional development and academic promotion of oncology professionals.
P2RY14 cAMP signaling regulates Schwann cell precursor self-renewal, proliferation, and nerve tumor initiation in a mouse model of neurofibromatosis
Cram, Jennifer Patritti , Wu, Jianqiang , Coover, Robert A, Rizvi, Tilat A, Chaney, Katherine E, Ravindran, Ramya, Cancelas, Jose A, Spinner, Robert J, Ratner, Nancy , Ravindran, Ramya , Patritti Cram, Jennifer , Wu, Jianqiang , Coover, Robert A, Rizvi, Tilat A, Chaney, Katherine E, Ravindran, Ramya, Cancelas, Jose A, Spinner, Robert J, Ratner, Nancy

Mayo Clinic

eLife | March 21, 2022 | Volume: 11 | Issue: No issue available | Pages: No page available

10.7554/elife.73511 | PMID 35311647 Get It

Neurofibromatosis type 1 (NF1) is characterized by nerve tumors called neurofibromas, in which Schwann cells (SCs) show deregulated RAS signaling. NF1 is also implicated in regulation of cAMP. We identified the G-protein-coupled receptor (GPCR) P2ry14 in human neurofibromas, neurofibroma-derived SC precursors (SCPs), mature SCs, and mouse SCPs. Mouse Nf1-/- SCP self-renewal was reduced by genetic or pharmacological inhibition of P2ry14. In a mouse model of NF1, genetic deletion of P2ry14 rescued low cAMP signaling, increased mouse survival, delayed neurofibroma initiation, and improved SC Remak bundles. P2ry14 signals via G i to increase intracellular cAMP, implicating P2ry14 as a key upstream regulator of cAMP. We found that elevation of cAMP by either blocking the degradation of cAMP or by using a P2ry14 inhibitor diminished NF1 -/- SCP self-renewal in vitro and neurofibroma SC proliferation in in vivo. These studies identify P2ry14 as a critical regulator of SCP self-renewal, SC proliferation, and neurofibroma initiation.